6 / 7
Page 56
allied
academies
J Med Oncl Ther 2017 Volume 2 | Issue 3
International Conference on
Oncology and Cancer Therapeutics
October 30- November 01, 2017 | Chicago, USA
Statement of the Problem:
Lung cancer remains one of the
leading causes of cancer-related death worldwide. Extending
the duration of treatment with the initial platinum based
chemotherapy beyond four to six cycles has been evaluated.
The aim of this study is to investigate efficacy and toxicity
of continuation maintenance treatment with pemetrexed
(Alimta) in patients displaying disease control after four cycles
of induction with cisplatin plus pemetrexed in advanced non
squamous (NSCLC).
Methodology & Theoretical Orientation:
Between April 2013
and April 2015, 16 patients with pathologically proven stage
III/IV, non-squamous NSCLC, in Clinical Oncology Department,
Tanta University Hospital and Tanta Insurance Hospital who
had received prior four cycles of induction with cisplatin
(75mg/m2) plus pemetrexed (500mg/m2) every 21 days
without disease progression were enrolled. Patients received
continuation maintenance treatment with pemetrexed
(500mg/m2 for every 21 days). The primary endpoints of the
study were the overall survival and progression-free survival.
Secondary end point was the safety profile.
Finding:
A total of 64 chemotherapy cycles of continuation
maintenance pemetrexed were administered. Patients
were treated with a median number of 4 cycles (range 2-30
cycles). Two patients received no more than 2 cycles due to
rapid disease progression. The estimated median PFS and
OS were 7.5 and 17 months, respectively. Treatment-related
adverse events were manageable with only 1 patient (6.25%)
suffered from Grade 3 anemia and another 1 patient (6.25%)
suffered from Grade 4 neutropenia. All patients received full
doses of pemetrexed throughout the study. There was no
treatment-related death.
Conclusion& Significance:
Using the continuationmaintenance
regimen with pemetrexed preceded by four cycles of induction
with cisplatin plus pemetrexed represents an obvious treatment
advance with an acceptable clinical profile for patients with
non-squamous NSCLC patients
e:
nesreensabry1eg@yahoo.comPreliminary results of continuation maintenance treatment with pemetrexedin advanced non-squamous
non-small cell lung cancer (NSCLC) patients after prior induction chemotherapy– single-arm phase II study
Nesreen M Sabry
Tanta University, Egypt